[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611773":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":84,"collaborators":19,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":19,"eligibilityCriteria":91,"healthyVolunteers":88,"sex":92,"minAge":93,"maxAge":19,"enrollmentInfo":94,"targetDuration":19,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Abbott Medical Devices","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cephea TMVR","EXPERIMENTAL","Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System",[13],"Device: Cephea Mitral Valve System",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Cephea Mitral Valve System",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Barathi Sethuraman","Abbott Structural Heart","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Leslie Centeno","CONTACT","+1 818-294-3041","leslie.centeno@abbott.com",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":33},"Clinical Project Manager","Cephea_FS@abbott.com",[35,55,72],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Instituto do Coracao (InCor) - HCFMUSP","RECRUITING","São Paulo","05403-900","Brazil","BR",{"type":43,"coordinates":44},"Point",[45,46],-46.63611,-23.5475,{"lat":46,"lon":45},[49,52],{"name":50,"role":28,"phone":19,"phoneExt":19,"email":51},"Joao Mourao","joao.mourao@hc.fm.usp.br",{"name":53,"role":54,"phone":19,"phoneExt":19,"email":19},"Alexandre Abizaid","PRINCIPAL_INVESTIGATOR",{"facility":56,"status":37,"city":57,"state":19,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Instituto Nacional del Torax","Santiago","8320000","Chile","CL",{"type":43,"coordinates":62},[63,64],-70.64827,-33.45694,{"lat":64,"lon":63},[67,70],{"name":68,"role":28,"phone":19,"phoneExt":19,"email":69},"Patricia Sandoval","psandoval8@hotmail.com",{"name":71,"role":54,"phone":19,"phoneExt":19,"email":19},"Jorge Sandoval",{"facility":73,"status":37,"city":57,"state":19,"zip":74,"country":59,"countryCode":60,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Hospital Clinico San Borja Arriarán","8360160",{"type":43,"coordinates":76},[63,64],{"lat":64,"lon":63},[79,82],{"name":80,"role":28,"phone":19,"phoneExt":19,"email":81},"Maria Jesus Vergara","Mvergara@inncardio.com",{"name":83,"role":54,"phone":19,"phoneExt":19,"email":19},"Gabriel Maluenda",{"type":85,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100611773","cephea-south-america-feasibility-study-100611773",false,"NCT07244939","Cephea South America Feasibility Study","Key Inclusion Criteria:\n\n* Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and\u002For severe mitral valve stenosis (mitral valve area ≤ 1.5cm²) per American Society of Echocardiography criteria\n* LVEF ≥ 30%\n* In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery\n\nKey Exclusion Criteria:\n\n* Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function\n* Need for emergent or urgent surgery","ALL","18 Years",{"count":95,"type":96},20,"ESTIMATED","INTERVENTIONAL",[99],"NA","The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.",[102,103],"Mitral Regurgitation","Mitral Stenosis",[105,17],"Symptomatic mitral valve disease","2026-02-05",{"date":108,"type":109},"2026-02-06","ACTUAL",{"date":111,"type":109},"2025-06-17",{"date":113,"type":96},"2028-09",{"name":5,"class":6},3]